FrancophonIA/ELRC3.0 huggingface dataset:
English: It has comparable biochemical properties to natural human Thyroid Stimulating Hormone (TSH).
Maltese: Thyrogen fih is-sustanza attiva thyrotropin alfa Thyrogen hu ormon li jistimula t-tirojde umana (TSH)
English: • neck pain
Maltese: • jekk inti tqila
English: For thyroglobulin (Tg) testing, your doctor or nurse will take a serum sample 72 hours after the last injection of Thyrogen.
Maltese: Fil-każ tal-ittestjar ta' thyroglobulin (Tg), it-tabib jew l-infermiera tiegħek ser jieħdu kampjun tas serum 72 siegħa wara l-aħħar injezzjoni ta' Thyrogen.
English: Total number of patients with recurrence
Maltese: NUMRI TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ
English: A risk to the suckling child cannot be excluded.
Maltese: Irriskju gћat-trabi tat-twelid li jkunu qed jerdgħu ma jistax jiġi eskluż.
English: Two large prospective randomised studies, the HiLo study (Mallick) and the ESTIMABL1 study (Schlumberger), compared methods of thyroid remnant ablation in patients with differentiated thyroid cancer who had been thyroidectomised.
Maltese: u l-istudju ESTIMABL1 (Schlumberger) ipparagunaw metodi ta' tneħħija ta' fdal tat-tirojde f'pazjenti li kellhom kanċer tat-tirojde li hu differenzjat sewwa u li kellhom tirojdektomija.
English: Withdraw 1.0 ml of the Thyrogen solution from the product vial.
Maltese: Iġbed 1.0 ml ta' soluzzjoni ta' Thyrogen mill-kunjett tal-prodott.
English: The success of thyroid remnant ablation also was assessed by the criterion of Thyrogen-stimulated serum Tg level < 2 ng/ml eight months after ablation, but only in patients who were negative for interfering anti-Tg antibodies.
Maltese: Is-suċċess tal asportazzjoni tal-fdal tat-tirojde kien evalwat ukoll bil-kriterju tal-livell ta' < 2 ng/ml ta' Tg fis-serum stimulat minn Thyrogen tmien xhur wara l-asportazzjoni, imma għal pazjenti li kienu negattivi għall antikorpi anti-Tg li jinterferixxu biss.
English: Diagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration, whereas post-ablation scintigraphy may be delayed additional days to allow background activity to decline.
Maltese: Xintigrafija dijanjostika għandha ssir fi żmien 48 sa 72 siegħa wara l-għoti tal-jodju radjoattiv, filwaqt li x-xintegrafija ta' wara l-asportazzjoni għandha mnejn tiġi mtawla bi ġranet addizzjonali biex tippermetti t-tnaqqis tal-attività fl-isfond.
English: The long term follow-up data in ESTIMABL1 and HiLo confirmed similar outcomes for patients in all four treatment groups.
Maltese: Id-data ta' segwitu fit-tul f'ESTIMABL1 u HiLo kkonfermat riżultati simili għall-pazjenti fl-erba' gruppi kollha tat-trattament.
English: Nervous system disorders dizziness, headache ageusia, dysgeusia, paraesthesia stroke, tremor
Maltese: żviluppa fibrillazzjoni atrijali, dikompensazzjoni kardijaka u infart mijokardjali terminali jumejn wara.
English: This may lead to acute symptoms, which depend on the anatomical location of the tissue e.g. hemiplegia, hemiparesis, loss of vision have occurred in patients with CNS metastases.
Maltese: Dan jista' jwassal għal sintomi akuti li jiddependu mis-sit anatomiku tat-tessut, eż. emipleġja, emiparesi, telf tal-vista seħħew f'pazjenti b'metastasi tas-SNĊ.
English: Patients with renal/hepatic impairment
Maltese: Pazjenti b'indeboliment tal-kliewi/fwied
English: In these studies the use of thyroglobulin testing on Thyrogen was found to be more sensitive than thyroglobulin testing on TSHT.
Maltese: L-effetti li ġejjin ġew irrappurtati fi studji kliniċi b'Thyrogen:
English: Manifestations of hypersensitivity have been reported uncommonly in both clinical and post-marketing settings.
Maltese: Manifestazzjonijiet ta' sensittività eċċessiva ġew irrappurtati mhux daqshekk ta' spiss f'ambjenti kemm kliniċi u ta' wara t-tqegħid fis-suq.
English: False negative results may occur with Thyrogen.
Maltese: Thyrogen jikkaġuna wkoll tkabbir fit-tumur.
English: For optimal diagnosis of thyroid remnants or cancer via either radioiodine imaging or thyroglobulin testing and for radioiodine therapy of thyroid remnants, a high serum level of TSH is needed to stimulate either radioiodine uptake and/or thyroglobulin release.
Maltese: Fi provi kliniċi b'thyrotropin alfa, li jikkawża żieda fil-livelli tat-TSH fis-serum għal żmien qasir, ma ġie rrappurtat l-ebda każ ta' żvilupp ta' tumur.
English: Success of remnant ablation was assessed with radioiodine imaging and with serum thyroglobulin testing at 8 ± 1 months after treatment.
Maltese: Is-suċċess ta' asportazzjoni tal-fdal kien evalwat b'immaġini ta' jodju radjuattiv u b'testijiet ta' thyroglobulin fis-serum, 8 ± 1 xhur wara t-trattament.
English: White to off-white lyophilised powder.
Maltese: tingħata permezz ta' injezzjoni ġol-muskoli fil-warrani.
English: Justification for not including Braille accepted.
Maltese: Il-ġustifikazzjoni biex ma jkunx inkluż il-Braille hi aċċettata.
English: • pain (including pain at the site of metastases (secondary cancer growths))
Maltese: • uġigħ (li jinkludi wġigħ fis-sit tal-metastasi (tkabbir ta' kanċer sekondarju))
English: MSD France
Maltese: FR MSD France
English: 15 to 18 days
Maltese: 15 sa 18-il jum
English: • 6 syringes
Maltese: • 6 siringi
English: 400 mg twice daily 18 14.1 (121 %)
Maltese: 400 mg darbtejn kuljum 18 14.1 (121%)
English: (increased solubility)
Maltese: (żieda fis-solubilità)
English: • atazanavir (an antiretroviral medication)
Maltese: • atazanavir (medikazzjoni antiretrovirali)
English: 1.5 mg/kg once daily 25 38.2 (38.4%)
Maltese: 1.5 mg/kg darba kuljum 25 38.2 (38.4%)‡
English: per 100 PYR, respectively.
Maltese: PYR, rispettivament.
English: After mixing Isentress, use it within 30 minutes.
Maltese: Wara li tħallat Isentress, użah fi żmien 30 minuta.
English: Gender, race and BMI
Maltese: Sess, razza u BMI
English: • tipranavir/ritonavir (antiretroviral medicines)
Maltese: • tipranavir/ritonavir (mediċini antiretrovirali)
English: Granules for oral suspension.
Maltese: Granuli għal sospensjoni orali.
English: In vitro, raltegravir is a weak inhibitor of organic anion transporter (OAT) 1 (IC50 of 109 µM) and OAT3 (IC50 of 18.8 µM).
Maltese: In vitro, raltegravir huwa inibitur dgħajjef ta' trasportatur tal-anjon organiku (OAT) 1 (IC50 ta' 109 µM) u OAT3 (IC50 ta' 18.8 µM).
English: Virologic failure
Maltese: Indeboliment viroloġiku
English: System Organ Class
Maltese: Sistema tal-Klassifika tal
English: 3 to less than 20 kg Oral suspension
Maltese: 3 sa inqas minn 20 kg Sospensjoni orali
English: Viral Subtype Clade B
Maltese: Sottotip Virali Clade B Non-Clade B
English: for 3.5 mL to 10 mL
Maltese: għal 3.5 mL sa 10 mL
English: 3.0 mg/kg twice daily 23 14.3 (43.3%)
Maltese: 3.0 mg/kg darbtejn kuljum 23 14.3 (43.3%) §
English: Uncommon palpitations, sinus bradycardia, ventricular extrasystoles
Maltese: Mhux komuni palpitazzjonijiet, bradikardija fis-sinus, ekstrasistoles ventrikulari
English: Muscle problems
Maltese: Problemi fil-muskoli
English: The active substance is raltegravir.
Maltese: Is-sustanza attiva hi raltegravir.
English: • mental disorder
Maltese: • disturb mentali
English: • allergic rash
Maltese: • raxx allerġiku
English: 25 to less than 28
Maltese: 25 sa inqas minn 28
English: See section 5.1.
Maltese: 5.1 u 5.2).
English: Note before adding Isentress:
Maltese: Nota qabel iżżid Isentress:
English: *Number of patients with intensive pharmacokinetic (PK) results at the final recommended dose.
Maltese: *Numru ta' pazjenti b'riżultati farmakokinetiċi (PK) intensivi bid-doża rakkomandata finali.
English: Geometric Mean (%CV AUC (mg*hr/L)
Maltese: Medja Ġeometrika (%CV†) AUC (mg*hr/L)
English: Placebo +
Maltese: Placebo + OBT
English: BLUE
Maltese: BLU
English: HORMONAL CONTRACEPTIVES Ethinyl Estradiol
Maltese: KONTRAĊETTIVI ORMONALI Ethinyl Estradiol Norelgestromin
English: (Increased drug solubility)
Maltese: (Żieda fis-solubilità tal mediċina)
English: • 60 sachets of Isentress granules
Maltese: • 60 qartas ta' Isentress granuli
English: Raltegravir 1,200 mg QD and raltegravir 400 mg BID were administered with emtricitabine (+) tenofovir disoproxil fumarate.
Maltese: Raltegravir 1,200 mg QD u raltegravir 400 mg BID ingħataw ma' emtricitabine (+) tenofovir disoproxil fumarate.
English: OBT (N = 237)
Maltese: (N = 237)
English: See section 4.2 for dosing recommendations.
Maltese: Ara sezzjoni 4.2 għal rakkomandazzjonijiet dwar id-dożaġġ.
English: 2 to less than 3
Maltese: 2 sa inqas minn 3
English: ≤ 100,000 copies/mL CD4-count ≤ 200 cells/mm > 200 cells/mm Viral Subtype Clade B Non-Clade B 93.6 (89.1, 96.6) 93.2 (84.9, 97.8) 89.5 (84.1, 93.6) 94.4 (86.2, 98.4)
Maltese: > 200 ċellola/mm3 Sottotip Virali Clade B Mhux Clade B B 93.6 (89.1, 96.6) 93.2 (84.9, 97.8) 89.5 (84.1, 93.6) 94.4
English: Use a clock or timer to time for 45 seconds.
Maltese: Uża arloġġ jew timer għal 45 sekonda.
English: Check for air bubbles
Maltese: Air bubbles - Bżieżaq tal-arja)
English: Film-coating - Lactose monohydrate - Hypromellose 2910 - Titanium dioxide - Triacetin - Iron oxide yellow - Black iron oxide
Maltese: - Lactose monohydrate - Hypromellose 2910 - Titanium dioxide - Triacetin - Iron oxide yellow - Black iron oxide
English: Isentress is an antiviral medicine that works against the Human Immunodeficiency Virus (HIV).
Maltese: Isentress huwa mediċina antivirali li taħdem kontra l-Virus ta' Immunodefiċjenza Umana (HIV).
English: Sensitivity score (GSS)
Maltese: Punteġġ tas-sensittività (GSS)
English: Common rash
Maltese: Komuni raxx
English: (chelation of metal ions)
Maltese: (chelation ta' joni tal-metall)
English: Contains fructose, sorbitol and aspartame.
Maltese: Fih fructose, sorbitol u aspartame.
English: ISENTRESS granules for oral suspension contain fructose, sorbitol and sucrose.
Maltese: ISENTRESS granuli għal sospensjoni orali fihom il-fructose, sorbitol u sucrose.
English: Geometric mean (%CV C12hr (nM)
Maltese: (%CV†) C12hr (nM)
English: Excipients with known effect Each sachet contains approximately: 0.5 mg fructose, 1.5 mg sorbitol and 4.7 mg sucrose.
Maltese: Kull qartas fih madwar 0.5 mg fructose, 1.5 mg sorbitol u 4.7 mg sucrose.
English: Stop when you get to the 10 mL mark.
Maltese: Ieqaf meta tasal sal-marka ta' 10 mL.
English: Raltegravir is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus (HIV-1).
Maltese: Raltegravir huwa inibitur tat-trasferiment tal-istrand integrase attiv kontra l-Virus talImmunodefiċjenza Umana (HIV-1).
English: atazanavir (raltegravir 1,200 mg single dose)
Maltese: atazanavir (raltegravir 1,200 mg doża waħda)
English: (chelation of metal cations)
Maltese: (chelation ta' cations tal metall)
English: Isentress contains the active substance raltegravir.
Maltese: Isentress fih is-sustanza attiva raltegravir.
English: These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Maltese: Dawn jinkludu każijiet tas-sindrome ta' Stevens-Johnson u nekrolisi tossika tal-epidermide.
English: UGT1A1 Polymorphism
Maltese: Polymorfiżmu UGT1A1
English: for 1 mL or less for 1.5 mL to 3 mL
Maltese: għal 1 jew inqas għal 1.5 mL sa 3 mL
English: • Granules for oral suspension should be given to the patient within 30 minutes of mixing.
Maltese: • Granuli għal sospensjoni orali għandhom jingħataw lill-pazjent għallinqas 30 minuta wara r rikostituzzjoni.
English: 3 to less than 4
Maltese: 3 sa inqas minn 4
English: The SWITCHMRK 1 & 2 (Protocols 032 & 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA < 50 copies/mL; stable regimen > 3 months) therapy with lopinavir 200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomised them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively).
Maltese: L-istudji SWITCHMRK 1 u 2 (Protokolli 032 u 033) evalwaw pazjenti infettati bl-HIV li rċevew terapija soppressiva (HIV RNA tal-iskrining < 50 kopja/mL; reġim stabbli > 3 xhur) b'lopinavir 200 mg (+) ritonavir 50 mg 2 pilloli darbtejn kuljum u mill-anqas 2 inibituri nucleoside reverse transcriptase u ġew randomizzati 1:1 biex ikomplu lopinavir (+) ritonavir 2 pilloli darbtejn kuljum (n=174 u n=178, rispettivament) jew jissostitwixxu lopinavir (+) ritonavir b'raltegravir 400 mg darbtejn kuljum (n=174 u n=176, rispettivament).
English: Raltegravir at concentrations of 31  20 nM resulted in 95 % inhibition (IC95) of HIV-1 replication (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures infected with the cell-line adapted HIV-1 variant H9IIIB.
Maltese: Konċentrazzjonijiet ta' raltegravir fi 31 ± 20 nM irriżultaw f'impediment ta' 95% (IC95) tarreplikazzjoni virali (meta mqabbla ma' kultura infettata bil-virus mhux ittrattata) f'kulturi ta' ċelloli Tlimfojde umani infettati b'H9IIIB, varjant HIV-1 tal-linja taċ-ċellola adatta.
English: Dose (See Table 2)
Maltese: Doża (Ara Tabella 2) N*
English: > 50 and ≤ 200 cells/mm
Maltese: > 50 u ≤ 200 ċellola/mm3
English: Adults and paediatric population
Maltese: Pazjenti adulti u popolazzjoni pedjatrika
English: Inhibitors of UGT1A1
Maltese: Inibituri ta' UGT1A1
English: Tablet core - Microcrystalline cellulose - Lactose monohydrate - Calcium phosphate dibasic anhydrous - Hypromellose 2208 - Poloxamer 407 - Sodium stearyl fumarate - Magnesium stearate
Maltese: - Microcrystalline cellulose - Lactose monohydrate - Calcium phosphate dibasic anhydrous - Hypromellose 2208 - Poloxamer 407 - Sodium stearyl fumarate - Magnesium stearate
English: In patients, after 1,200 mg once daily raltegravir dosing, steady state AUC0-24 was 53.7 h·μM, C24 was 75.6 nM, and median Tmax was 1.50 h.
Maltese: F'pazjenti, wara d-dożaġġ ta' raltegravir 1,200 mg darba kuljum, l-istat AUC0-24 fiss kien 53.7 h·μM, C24 kien 75.6 nM, u medjan Tmax kien 1.50 h.
English: 0.8 mL (8 mg) twice daily
Maltese: 0.8 mL (8 mg) darbtejn kuljum
English: Studies using isoform-selective chemical inhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1 is the main enzyme responsible for the formation of raltegravir-glucuronide.
Maltese: Studji b'inibituri kimiċi iżoformi-selettivi u cDNA-expressed UDPglucuronosyltransferases (UGT) juru li UGT1A1 hija l-enzima ewlenija responsabbli għal formazzjoni ta' raltegravir-glucuronide.
English: Tablet core - Microcrystalline cellulose - Hypromellose 2910 - Magnesium stearate - Croscarmellose sodium
Maltese: Fuq ġewwa tal-pillola - Microcrystalline cellulose - Hypromellose 2910 - Magnesium stearate - Croscarmellose sodium
English: Additional side effects in children and adolescents • hyperactivity
Maltese: Effetti sekondarji addizzjonali fit-tfal u l-adolexxenti • attività eċċessiva
English: Pharmacotherapeutic group: antivirals for systemic use, other antivirals, ATC code: J05AX08.
Maltese: Kategorija farmakoterapewtika: antivirali għal użu sistemiku, antivirali oħra, Kodiċi ATC:
English: Most had a signature mutation at amino acid 155 (N155 changed to H), amino acid 148 (Q148 changed to H, K, or R), or amino acid 143 (Y143 changed to H, C, or R), along with one or more additional integrase mutations (e.g., L74M, E92Q, T97A, E138A/K, G140A/S, V151I, G163R, S230R).
Maltese: Il biċċa l-kbira kellhom signature mutation fl-aċidu amminiku 155 (N155 inbidel għal H), l-aċiduamminiku 148 (Q148 inbidel għal H, K, jew R), jew l-aċidu amminiku 143 (Y143 inbidel għal H, C, jew R), flimkien ma' bidla waħda jew aktar addizzjonali ta' integrase (e.g., L74M, E92Q, T97A, E138A/K, G140A/S, V151I, G163R, S230R).
English: Uncommon erectile dysfunction, gynaecomastia, menopausal symptoms
Maltese: Mhux komuni impotenza, ginekomastija, sintomi tal-menopawsa
English: Once absorbed, both formulations of raltegravir exhibit similar systemic pharmacokinetics.
Maltese: Ladarba assorbiti, iż-żewġ formulazzjonijiet ta' raltegravir jeżibixxu farmakokinetiċi sistematiċi simili.
English: Date of first authorisation: 20 December 2007 Date of latest renewal: 14 May 2014
Maltese: Data tal-aħħar tiġdid: 14 ta' Mejju 2014
English: gastric pH altering agents: proton pump inhibitors (e.g. omeprazole), H2 blockers (e.g. famotidine, ranitidine, cimitedine)
Maltese: aġenti li jibdlu l-pH gastriku: inibituri tal-pompa tal-proton (eż. omeprazole), impedituri H2 (eż. famotidine, ranitidine, cimitedine)
English: 0.5 mL (5 mg) once daily
Maltese: 0.5 mL (5 mg) darba kuljum
English: 4 to less than 5
Maltese: 4 sa inqas minn 5
English: • rifampicin (a medicine used to treat some infections such as tuberculosis)
Maltese: • rifampicin (mediċina użata biex jiġu tikkura xi infezzjonijiet bħat-tuberkulożi)
English: Each chewable tablet contains approximately 0.93 mg fructose, approximately 0.10 mg phenylalanine (as a component of aspartame) and approximately 2.8 mg sorbitol.
Maltese: Eċċipjenti b'effett magħruf ta' 100mg Kull pillola li tomgħodha fiha madwar 0.93 mg fructose, madwar 0.10 mg phenylalanine (bħala komponent ta' aspartame) u madwar 2.8 mg sorbitol.
English: 0.4 mL (4 mg) once daily
Maltese: 0.4 mL (4 mg) darba kuljum
English: maraviroc AUC  14 % maraviroc C12hr  10 % maraviroc Cmax ↓ 21 %
Maltese: maraviroc C12hr ↓ 10% maraviroc Cmax ↓ 21%
English: ISENTRESS 600 mg tablet formulation has not been studied in paediatric patients (see section 4.2).
Maltese: Il-formulazzjon tal-pillola ISENTRESS 600 mg pillola ma ġietx studjata f'pazjenti pedjatriċi (ara sezzjoni 4.2).
English: Raltegravir and efavirenz were administered with emtricitabine (+) tenofovir disoproxil fumarate.
Maltese: Raltegravir u efavirenz ingħataw ma' emtricitabine (+) tenofovir disoproxil fumarate.
English: Note: The chewable tablets are available as 25 mg and 100 mg tablets.
Maltese: Nota: Il-pilloli li tomgħodhom jiġu bħala 25 mg u 100 mg pilloli. ‡
English: This is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).
Maltese: Dan huwa l-virus li jikkawża l-Acquired Immune Deficiency Syndrome (AIDS).
English: The treatment difference (raltegravir 1,200 mg once daily-raltegravir 400 mg twice daily) was 1.5 % with an associated 95 % CI of (-4.4, 7.3).
Maltese: Id-differenza fit-trattament (raltegravir 1,200 mg darba kuljum-raltegravir 400 mg darbtejn kuljum) kienet 1.5 % b'CI ta' 95 % assoċjat ta' (-4.4, 7.3).
English: Population PK analysis showed that the effect of emtricitabine/tenofovir disaproxil fumarate on raltegravir pharmacokinetics was minimal (12% increase in relative bioavailability), and was not statistically or clinically significant.
Maltese: emtricitabine/tenofovir disaproxil fumarate fuq ilfarmakokinetiċi ta' raltegravir kien minimu (żieda ta' 12% filbiodisponibbiltà relattiva), u ma kienx statistikament jew klinikament sinifikanti.
English: Excipient with known effect Each 600 mg tablet contains 5.72 mg lactose (as monohydrate).
Maltese: Eċċipjent b'effett magħruf Kull pillola ta' 600 mg fiha 5.72 mg lactose (bħala monohydrate).
English: • suicide intention or attempt
Maltese: • intenzjoni jew attentat ta' suwiċidju
English: At the NOAEL, systemic exposure was similar to that at the clinical dose of 400 mg twice daily.
Maltese: Fin-NOAEL, l-esponiment sistemiku kien simili għal dak fid-doża klinika ta' 400 mg darbtejn kuljum.
English: In interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of etravirine, maraviroc, tenofovir disoproxil fumarate, hormonal contraceptives, methadone, midazolam or boceprevir.
Maltese: Fi studji ta' interazzjoni, raltegravir ma kellux effett klinikament sinifikanti fuq il-farmakokinetiċi ta' etravirine, maraviroc, tenofovir disoproxil fumarate, kontraċettivi ormonali, methadone, midazolam jew boceprevir.
English: ISENTRESS should be used in combination with other active anti-retroviral therapies (ARTs) (see sections 4.4 and 5.1).
Maltese: ISENTRESS għandu jintuża flimkien ma' terapiji antiretrovirali (ARTs) attivi oħra (ara sezzjonijiet 4.4 u 5.1).
English: Efavirenz 600 mg at bedtime (N = 282)
Maltese: 600 mg fil-ħin tal irqad (N = 282)
English: Film-coating - Polyvinyl alcohol - Titanium dioxide - Polyethylene glycol 3350 - Talc - Red iron oxide - Black iron oxide
Maltese: - Polyvinyl alcohol - Titanium dioxide - Polyethylene glycol 3350
English: 156 cells/mm
Maltese: 156 ċelluli/mm3
English: ANTI-RETROVIRAL Protease inhibitors (PI) atazanavir /ritonavir (raltegravir 400 mg Twice Daily)
Maltese: Inibituri protease (PI) atazanavir /ritonavir (raltegravir 400 mg Darbtejn Kuljum)
English: HIV genomes that fail to integrate cannot direct the production of new infectious viral particles, so inhibiting integration prevents propagation of the viral infection.
Maltese: Ġenomi talHIV li jonqsu milli jintegraw ma jistgħux jidderieġu l-produzzjoni ta' partikuli virali infettivi ġodda, allura impediment ta' integrazzjoni ma jħallix propagazzjoni tal-infezzjoni virali.
English: ISENTRESS 100 mg granules Raltegravir
Maltese: ISENTRESS 100 mg granuli Raltegravir
English: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (raltegravir 400 mg Single Dose)
Maltese: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
English: Raltegravir is approximately 83 % bound to human plasma protein over the concentration range of 2 to 10 µM.
Maltese: Raltegravir huwa madwar 83% marbut mal-proteina fil-plażma fuq firxa ta' konċentrazzjoni ta' 2 sa 10 µM.
English: ISENTRESS 600 mg film-coated tablets is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, and paediatric patients weighing at least 40 kg (see sections 4.2, 4.4, 5.1 and 5.2).
Maltese: ISENTRESS 600 mg pilloli miksija b'rita huwa indikat f'kombinazzjoni ma' prodotti mediċinali antiretrovirali oħra għat-trattament ta' infezzjoni bil-virus tal-immunodefiċjenza tal-bniedem (HIV-1) f'persuni adulti, u f'pazjenti pedjatriċi li jiżnu talanqas 40 kg (ara sezzjonijiet 4.2, 4.4, 5.1 u 5.2).
English: Week 48 and Week 96 outcomes from ONCEMRK are shown in Table 4.
Maltese: Irriżultati ta' Ġimgħa 48 u Ġimgħa 96 minn ONCEMRK huma murija f'Tabella 4.
English: 119 cells/mm
Maltese: 119 ċelluli/mm3
English: Nucleoside/tide reverse transcriptase inhibitors tenofovir disoproxil fumarate (raltegravir 400 mg Twice Daily)
Maltese: Nucleoside/tide reverse transcriptase inhibitors tenofovir disoproxil fumarate
English: Pink, oval tablet, marked with "227" on one side.
Maltese: Pillola roża, ovali, immarkata b'"227" fuq naħa waħda.
English: The initial dose finding stage included intensive pharmacokinetic evaluation.
Maltese: L-istadju inizjali ta' sejbien tad-doża kien jinkludi evalwazzjoni farmakokinetika intensiva.
English: • feeling dizzy; headache
Maltese: • sturdament; uġigħ ta' ras
English: Raltegravir achieved virologic responses (using Not Completer=Failure approach) of HIV RNA < 50 copies/mL in 61.7 % of patients at Week 16, in 62.1 % at Week 48 and in 57.0 % at Week 96.
Maltese: Raltegravir laħaq risponsi viroloġiċi (permezz tal-metodu Mhux Mlesti = Falliment) għal HIV RNA < 50 kopja/mL f'61.7% tal-pazjenti f'Ġimgħa 16 u 62.1% f'Ġimgħa 48 u f'57.0% f'Ġimgħa 96.
English: Contains fructose, sorbitol and sucrose.
Maltese: TA' EĊĊIPJENTI Fih fructose, sorbitol u sucrose.
English: • visual disturbance
Maltese: • disturbi fil-vista
English: Anti-retroviral Pregnancy Registry
Maltese: Reġistru ta' Tqala Antiretrovirali
English: After reconstitution: 30 minutes when stored at or below 30 C.
Maltese: Wara r-rikostituzzjoni: 30 minuta meta maħżun f'temperatura ta' 30° C jew inqas.
English: Population PK analysis showed that the effect of gastric pH altering agents on raltegravir pharmacokinetics was minimal (8.8% decrease in relative bioavailability), and was not statistically or clinically significant.
Maltese: Analiżi PK tal-popolazzjoni uriet li l-effett tal-aġenti li jibdlu l-pH gastriku fuq ilfarmakokinetiċi ta' raltegreavir kien minimu (nuqqas ta' 8.8% fil-biodisponibbiltà relattiva); u ma kienx statistikament jew klinikament sinifikanti.